| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-04-20 | CA-170 | preclinical | Curis (USA - MA) Aurigene (India) | Cancer - Oncology | |
| 2016-04-20 | CA-4948 | preclinical | Curis (USA - MA) Aurigene (India) | Cancer - Oncology | |
| 2016-04-20 | AUPM-327 | preclinical | Curis (USA - MA) Aurigene (India) | Cancer - Oncology | |
| 2016-04-19 | sacituzumab govitecan - IMMU-132 | relapsed or refractory metastatic urothelial cancer | 2 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2016-04-19 | emixustat hydrochloride | geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) | 2b-3 | Acucela (USA - MA) Otsuka Pharmaceuticals (Japan) | Ophtalmological diseases |
| 2016-04-19 | ABP 798 (biosimilar version of Mabthera®/Rituxan® - rituximab) | non-Hodgkin lymphoma | 3 | Amgen (USA - CA) | Cancer - Oncology |
| 2016-04-19 | lenvatinib in combination with everolimus | kidney cancer | preclinical | Eisai (Japan) | Cancer - Oncology |
| 2016-04-19 | GITRL-Fc | preclinical | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology | |
| 2016-04-19 | new generation oncolytic viral immunotherapy product candidate | preclinical | Transgene (France) | Cancer - Oncology | |
| 2016-04-19 | IPH52 | preclinical | Innate Pharma (France) Orega Biotech (France) | Cancer - Oncology | |
| 2016-04-19 | AP32788 | preclinical | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology | |
| 2016-04-19 | IMO-2125 in combination with an inhibitor of the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO1) | Idera Pharmaceuticals (USA - CA) | Cancer - Oncology | ||
| 2016-04-18 | IMMU-114 | chronic lymphocytic leukemia, acute lymphoblastic leukemia | preclinical | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2016-04-18 | PEG-ADA2 | preclinical | Halozyme Therapeutics (USA - CA) | Cancer - Oncology | |
| 2016-04-18 | HTI-1511 | preclinical | Halozyme Therapeutics (USA - CA) | Cancer - Oncology | |
| 2016-04-18 | varlilumab and Opdivo® (nivolumab) | advanced non-small cell lung cancer (NSCLC), metastatic melanoma (MEL), colorectal cancer (CRC), ovarian cancer, and head and neck squamous cell carcinoma (SCCHN) | 1-2a | Celldex Therapeutics (USA - NJ) BMS (USA - NY) | Cancer - Oncology |
| 2016-04-18 | ARC-HIF2 | clear cell renal cell carcinoma | preclinical | Arrowhead Research Corporation (USA - CA) | Cancer - Oncology |
| 2016-04-18 | AZD2014 (vistusertib) | diffuse large B-cell mymphoma | 2 | AstraZeneca (UK) University of Birmingham (UK) | Cancer - Oncology |
| 2016-04-18 | TGR-1202 | preclinical | TG Therapeutics (USA - NY) | ||
| 2016-04-18 | Livatag® (doxorubicin Transdrug®) | hepatocellular carcinoma | Onxeo (France) | Cancer - Oncology |
